8-K
Perspective Therapeutics, Inc. (CATX)
View as plain text
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): May 04, 2026 |
|---|
Perspective Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-33407 | 41-1458152 |
|---|---|---|
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| c/o Perspective Therapeutics, Inc.<br><br>2401 Elliott Avenue<br><br>Suite 320 | ||
| Seattle, Washington | 98121 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s Telephone Number, Including Area Code: (206) 676-0900 | ||
| --- |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.001 par value | CATX | NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 4, 2026, Perspective Therapeutics, Inc. (the “Company”) posted to its website a presentation (the “Presentation”) containing slides presented at an analyst event hosted by the Company on that date and certain other slides regarding the Company’s clinical programs and manufacturing technologies and infrastructure. The Presentation contains certain estimated and projected financial information, including the Company’s estimated cash, cash equivalents and short-term investments as of March 31, 2026. The estimated and projected financial information included in the Presentation is preliminary and has not been audited, reviewed or compiled by the Company’s independent registered public accounting firm, WithumSmith+Brown, PC (“Withum”), and Withum has not completed its procedures with respect to the preliminary financial data. Accordingly, Withum does not express an opinion or any other form of assurance with respect thereto.
The Company’s actual results as of March 31, 2026 may differ from the preliminary financial data due to the completion of the Company’s closing procedures with respect to the quarter ended March 31, 2026, final adjustments and other developments that may arise between now and the time the financial results for the such fiscal quarter are finalized.
Item 8.01 Other Events.
On May 4, 2026, the Company posted the Presentation to its website. A copy of the Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
|---|---|
| 99.1 | Company Presentation. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PERSPECTIVE THERAPEUTICS, INC. | |||
|---|---|---|---|
| Date: | May 4, 2026 | By: | /s/ Joel Sendek |
| Joel Sendek<br>Chief Financial Officer |
Agenda
Engineering the Alpha Advantage in Targeted Oncology
Optimizing the Entire System
Expanding the Addressable Market
Unlocking New Treatment Options Across Solid Tumors:
Choosing The Right Isotope
Optimizing Structural Chemistry:
Not All ²¹²Pb Programs Are Created Equal
Advancing a Theranostic Approach:
A Decade of Deliberate, End-to-End Engineering
Direct-to-Hospital Delivery through Integrated Isotope Production
Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product
Reaching the Largest Addressable Market with Regional Manufacturing
Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Perspective Therapeutics
Theranostics in management of patients with neuroendocrine and other SSTR positive tumors
Objectives
Treatment landscape
Adverse side effects
Other factors that drive treatment
Survival expectations
NCCN guidelines
Treatment decision making
Alpha particle PRRT
The evolution of the treatment continuum
Summary
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs
Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
VMT-⍺-NET: Baseline Patient Characteristics in AACR 2026 Data Analysis
Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AACR 2026 Data Analysis
Blood Creatinine During Follow-up for All Patients Treated (n=64)
VMT-⍺-NET: Durable Disease Control Across All Doses
Spider plot of tumor change over time by patient
VMT-α-NET Responses Deepen Over Time
VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level
Why Frontloading?
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs
Meningioma
VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
[212Pb]Pb-VMT--NET after previous radio-ligand treatment
Dresden VMT--NET compassionate use program
Dresden VMT--NET compassionate use program
Dresden VMT--NET compassionate use program
Dresden VMT--NET compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
First results - compassionate use program
Case Study
Case Study
Case Study
Case Study
Imaging and dosimetry
Conclusion
How biodistribution informs therapeutic potential
Disclosures
PSMA vs DOTATATE
PSMA vs DOTATATE
PSMA vs DOTATATE
Patient’s journey from PSA>MRI>PSMA PET
Receptor Targeted PET enabled a fundamentally different clinical trial design: Treat if you see it
68Ga/177Lu-PSMA Super vs Non-Responder
68Ga/177Lu-DOTATATE Super vs Non-Responder
Radioligand Therapy Today “Science advances one funeral at a time” Max Planck
Radioligand Therapy Today “Science advances one funeral at a time” Max Planck
FAP is an Emerging Target
Not every FAP is bio-identical
Theranostics Short Half-lives for Long, Full Lives
FIH 203/212Pb Pb-VMT-α-NET Perspective Therapeutics
FIH 203/212Pb Pb-VMT-α-NET Perspective Therapeutics
Early, Medium and Late Biodistribution Should Inform Therapeutic Window
Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa
Development of PSV594 for CCK2R+ Tumor types
CCK2R: Implicated in Multiple Tumor Types With Major Unmet Needs
Expanding the Addressable Market
Optimizing the Entire System
A Decade of Deliberate, End-to-End Engineering
Built Over a Decade:
Q&A
Advancing a Theranostic Approach:
212Pb is Our Isotope of Choice
Choosing The Right Isotope
Kinetics Matter: 212Pb Hits Hard and Fast For Strong Activity with Less Systemic Exposure
𝜶-Particles Delivers More Potent, Targeted Tumor Killing vs. β-Particles
212Pb Further Enhanced by Proprietary Chelator for Targeted Delivery of Payload
212Pb Multi-Mechanistic Activity Drives Tumor Destruction and Anti-Tumor Immunity
Rationale for Synergy with Immune Checkpoint Inhibitors
212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors
212Pb Half-life Is More Convenient for Customers
Advancing a Theranostic Approach:
Supply Chain and Manufacturing Infrastructure
End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway
Direct-to-Hospital Delivery through Integrated Isotope Production
Reliable, On-Demand 212Pb from 228Th and 224Ra
Flexible Scalable 224Ra Supply Enables Regional Manufacturing
Ideal for Regional Manufacturing
On-Demand Fulfillment at Regional Sites for Finished Product Delivery
Daily Production at Regional Sites Ensures Supply of Ready-to-administer Product
Reaching the Largest Addressable Market with Regional Manufacturing
Mature, Well-Established Distribution Networks
Network Approach Chosen by Novartis